Rapaflo Symptom Relief ≠ Clinical Evidence, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA objects to image and headline on Actavis webpage suggesting benign prostatic hyperplasia treatment improves sleep quality and work productivity; company has revised the site.
You may also be interested in...
Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.